TickerKhojComparison · NSE · data 2026-11-03
Dr. Lal PathLabs Limited vs Nephrocare Health Services Limited
In plain words
Size: Dr. Lal PathLabs Limited is about 5 times the market value of Nephrocare Health Services Limited.
Return on equity: Dr. Lal PathLabs Limited 21.6% vs Nephrocare Health Services Limited 9%.
Debt to equity: Dr. Lal PathLabs Limited 0.08 vs Nephrocare Health Services Limited 0.07.
Differences in the numbers, not a recommendation of either stock.
Side by side
19 metrics shown
| LALPATHLAB | NEPHROPLUS | |
|---|---|---|
| Price | ₹1,925.7 | ₹624.6 |
| Market cap | ₹31,681 cr | ₹6,274 cr |
| P/E | 59.4 | — |
| P/B | — | — |
| ROE | 21.6% | 9.0% |
| ROCE | 25.3% | 14.6% |
| Debt / equity | 0.08 | 0.07 |
| Operating margin | 23.0% | — |
| Dividend yield | 0.85% | 0.00% |
| Sales growth, 3 years (yearly) | 11.1% | 31.6% |
| Profit growth, 3 years (yearly) | 28.3% | — |
| 1-year return | 22.1% | 27.5% |
| Revenue, last 12 months | ₹2,891 cr | — |
| Net profit, last 12 months | ₹542 cr | — |
| Latest quarter | Jun 2026 | Sept 2026 |
| Quarter net profit | ₹170 cr | ₹34 cr |
| Quarter profit vs a year earlier | +28.0% | — |
| Promoter holding | 52.93% | 58.31% |
| Health check | Strong (8/10) | Strong (7.9/10) |
Common questions
Which earns a higher return on equity?
Dr. Lal PathLabs Limited (21.6% against 9.0%).
Which carries more debt?
Dr. Lal PathLabs Limited has the higher debt-to-equity ratio (0.08 against 0.07).